Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Ori Biotech and ImmuXell Announce Strategic Partnership and First Patient Dosed

Ori’s IRO® platform. The IIT is aiming to evaluate ImmuXell’s TCR-T therapy in patients with solid tumors harboring KRAS G12V mutations, including those with colorectal cancer, pancreatic cancer, and lung cancer — all among the deadliest and most...

SK bioscience Signs Technology Transfer Agreement with Colombia’s VECOL to Advance Local Vaccine Manufacturing in Latin America

project represents a major government-led initiative with a total investment of approximately US$260 million over the next 10 years. Under the framework, VECOL has been designated by the Colombian government as the lead implementing entity...

Presentations Highlight Results on LEROCHOL® (lerodalcibep-liga) Announced by LIB Therapeutics

genetically confirmed HoFH completed the 72-week, open-label, extension study, with mean and absolute LDL-C reductions of 19.1% and 1.44 mmol/L (55.7 mg/dL), respectively, at the 72-week primary endpoint. At week 72, mean ApoB was reduced by 12.7%...

Digi-Tech Pharma & AI Conference 2026

The 9th Annual Digi-Tech Pharma & AI conference, a premier Pharmaceutical Technology Conference, brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare...

Lundbeck Receives Marketing Authorization in South Korea for Vyepti® (eptinezumab) for the Preventive Treatment of Migraine

and sensitivity to light and sound. Migraine affects one in seven people and is a leading cause of disability worldwide.1 Approximately 11% of the population in Korea currently lives with migraine, a figure that may be underestimated.1,2 Despite...

Hologic to Present New Data Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

therapy beyond five years.2,3 More information on these findings will be presented at the 2026 ASCO Annual Meeting on June 1. The data come from a new analysis of the ongoing BCI Registry Study, which evaluates how physicians incorporate prognostic...

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

a biotechnology company developing first-in-class therapies targeting cancer stem cells, announced that its second ADAR1p150 protein crystallization experiment has successfully launched aboard the SpaceX CRS-34 commercial resupply mission to the...

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

(PEF) therapies for oncology and chronic lung disease, today announced that it received U.S. Food and Drug Administration 510(k) clearance for the Aliya® EX Generator for surgical ablation of soft tissue. The Aliya EX Generator expands the Aliya...

Peter Menziuso named EVP and President of BD Interventional

announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and a strong track record of driving growth...

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

that re-induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) resulted in complete responses (CR) in approximately 31% (4/13) of patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC)...

Biohack skin longevity with Futurecode Booster

the skin's intrinsic longevity pathways to visibly restore firmness, smoothness, and overall skin health." clinical claims 100% saw skin that looked lifted, deeply replenished, and more even-toned* *Results after 8 weeks. Based on a consumer...

Pathobiology 2026

Pathobiology 2026 – May 16-19, 2026, in Fort Myers, Florida. Similar to the past two Annual Meetings, Pathobiology 2026 will be a stand-alone meeting that will leverage our society’s unique strengths in the understanding of cellular and molecular...

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, ENHERTU followed by a taxane, trastuzumab, and...

IMFINZI plus neoadjuvant EV improved survival outcomes in muscle-invasive bladder cancer in the Phase III VOLGA trial

cancer has muscle-invasive disease, where the tumor invades the muscle wall of the bladder, without distant metastases.1,2 As many as 50% of patients are ineligible for cisplatin-based chemotherapy due to impaired renal function or...

Neurocritical care leaders will discuss NPi pupillometry in NeurOptics sessions at AACN NTI 2026.

SCRN, FAHA, FNCS, FCCM, will speak as part of NeurOptics' in-booth clinical education programming at AACN NTI 2026, May 17–20, in San Diego. NeurOptics will be exhibiting in Booth #1616. Olson will present "Evidence-Based Practice in Pupillometry"...

SUANNUTRA USA secures U.S. distribution rights for TetraSOD.

systems, influencing metabolism, immune function, and physical performance. Tetraselmis chuii was first identified in the 1950s and has long been used in aquaculture due to its rich nutritional profile, "We invested more than 20 years in developing...

MinuteClinic highlights improved access and outcomes through its clinically supervised weight-loss program

to patients living with conditions such as obesity, diabetes and cardiovascular disease. Obesity alone contributes nearly $173 billion in annual medical costs, while more than two in five U.S. adults have prediabetes — most of whom are unaware of...

Kerri McCullough Wood Named Chief Commercial Officer at Avid Bioservices

following her role as Chief Commercial Officer at TAPI, a division of Teva, where she led a global organization spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong...

BIZENGRI® (Zenocutuzumab-zbco) Wins FDA Approval for NRG1 Fusion-Positive Cholangiocarcinoma, Says Partner Therapeutics

for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This marks the first targeted therapy approved...

Miach Orthopaedics Appoints Jamal Rushdy as President & CEO

in partnership with the board of directors. McBrayer will remain president and CEO until Rushdy assumes the role on May 18. “Patrick joined Miach at a pivotal moment, as we were accelerating commercialization of the BEAR Implant,” said Joyce Erony,...